There’s no better time to catch a wave than when it’s just started.
So here are two S&P/ASX 200 Index (ASX: XJO) buy suggestions from experts that have just started their rally:
‘Poised to deliver strong earnings growth’
Netwealth Group Ltd (ASX: NWL) shares have been busy climbing 36% since late October.
Sequoia Wealth senior advisor Peter Day still likes the look of them.
“The company’s high quality investment platform is poised to deliver strong earnings growth driven by market share gains, in our view,” Day told The Bull.
Investors’ money is flowing into the investment tool.
“Funds under administration (FUA) stood at $78 billion at December 31, 2023.
“FUA increased by 24.9% for the year to December 31, 2023. FUA net inflows accounted for $9.5 billion and a positive market movement accounted for $6 billion.”
Unusually for a fintech, Netwealth shares pay out a dividend, which currently stands at 1.4% yield.
“This wealth management business offers an appealing outlook.”
Comeback year for this ASX 200 stock
The Resmed CDI (ASX: RMD) share price has been coming back hard after it fell off a cliff last reporting season.
Fears about the impact of GLP-1 weight loss drugs such as Ozempic sent the ASX 200 stock to a trough in late September, but it has soared 38% since.
Catapult Wealth portfolio manager Tim Haselum acknowledged that obesity is “a contributing factor” towards sleep apnoea, which ResMed’s devices treat.
ResMed, with its latest update, dispelled the scares from last year.
“In the second quarter of fiscal year 2024, the company grew revenue by 11% on a constant currency basis compared to the prior corresponding period,” said Haselum.
“We expect the sleep apnoea business to grow moving forward.”
According to CMC Invest, 18 out of 25 analysts rate the healthcare stock as a buy, just like Haselum.
The post ‘Appealing outlook’: 2 ASX 200 shares that just started their latest rally appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…
See The 5 Stocks
*Returns as of 10 November 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Here are the top 10 ASX 200 shares today
- Hoping to bag the ResMed dividend? You better be quick!
- Top brokers name 3 ASX shares to buy next week
- 3 ASX All Ords shares with ex-dividend dates in the next week
- Top ASX shares to buy in February 2024
Motley Fool contributor Tony Yoo has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Netwealth Group and ResMed. The Motley Fool Australia has positions in and has recommended Netwealth Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/oKclpYN
Leave a Reply